BYLVAY

Peak

odevixibat

NDAORALCAPSULEPriority Review
Approved
Jul 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
8

Mechanism of Action

Ileal Bile Acid Transporter Inhibitors

Pharmacologic Class:

Ileal Bile Acid Transporter Inhibitor

Clinical Trials (5)

NCT07185919N/ARecruiting

A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC) Who Take Odevixibat (Bylvay) in South Korea

Started Oct 2025
10 enrolled
Progressive Familial Intrahepatic Cholestasis
NCT06850038N/ARecruiting

A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment

Started Apr 2025
30 enrolled
Alagille Syndrome
NCT06258902N/ARecruiting

Odevixibat Pregnancy and Lactation Surveillance Program: A Study to Evaluate the Safety of Odevixibat During Pregnancy and/or Lactation

Started Sep 2023
20 enrolled
Pregnancy Related
NCT05426733Phase 3Enrolling By Invitation

An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia

Started Jul 2022
180 enrolled
Biliary Atresia
NCT05035030Phase 3Recruiting

Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome

Started Sep 2021
70 enrolled
Alagille Syndrome

Loss of Exclusivity

LOE Date
Nov 12, 2041
191 months away
Patent Expiry
Nov 12, 2041
Exclusivity Expiry
Jun 13, 2030

Patent Records (5)

Patent #ExpiryTypeUse Code
10011633
Nov 8, 2031
U-3648
10093697
Nov 8, 2031
U-3648
10487111
Nov 8, 2031
U-3648
10981952
Nov 8, 2031
U-3649
11732006
Nov 8, 2031
U-3186